stocks logo

APUS

Apimeds Pharmaceuticals US Inc
$
2.220
+0.13(6.220%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.400
Open
2.130
VWAP
2.20
Vol
152.34K
Mkt Cap
25.70M
Low
2.100
Amount
335.35K
EV/EBITDA(TTM)
--
Total Shares
11.58M
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
Show More

Valuation Metrics

The current forward P/E ratio for Apimeds Pharmaceuticals US Inc (APUS.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Apimeds Pharmaceuticals US Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
+34.09%
-364.37K
Operating Profit
FY2025Q1
YoY :
+35.73%
-402.40K
Net Income after Tax
FY2025Q1
YoY :
+66.67%
-0.05
EPS - Diluted

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

APUS News & Events

News

5.0
07-15Newsfilter
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
Sign Up For More News

FAQ

arrow icon

What is Apimeds Pharmaceuticals US Inc (APUS) stock price today?

The current price of APUS is 2.22 USD — it has increased 6.22 % in the last trading day.

arrow icon

What is Apimeds Pharmaceuticals US Inc (APUS)'s business?

arrow icon

What is the price predicton of APUS Stock?

arrow icon

What is Apimeds Pharmaceuticals US Inc (APUS)'s revenue for the last quarter?

arrow icon

What is Apimeds Pharmaceuticals US Inc (APUS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Apimeds Pharmaceuticals US Inc (APUS)'s fundamentals?

arrow icon

How many employees does Apimeds Pharmaceuticals US Inc (APUS). have?

arrow icon

What is Apimeds Pharmaceuticals US Inc (APUS) market cap?